Zan­tac lit­i­ga­tion: One suit down, many more to go, GSK says

GSK’s first sched­uled Zan­tac-can­cer tri­al has been dis­missed by the plain­tiff, the British phar­ma com­pa­ny said, while not­ing that it did not set­tle the claim and has not paid any­thing in ex­change for the vol­un­tary dis­missal.

But be­gin­ning next month, a hear­ing for GSK’s mul­ti-dis­trict Zan­tac-re­lat­ed can­cer law­suit will kick off in the South­ern Dis­trict of Flori­da, with the phar­ma com­pa­ny look­ing to ex­clude plain­tiffs’ cau­sa­tion ex­perts, GSK said in a state­ment on Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER